Agile Therapeutics, Inc. (NASDAQ:AGRX) Short Interest Update

Posted by Defense World Staff on Aug 26th, 2023

Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 20,700 shares, a decline of 46.2% from the July 31st total of 38,500 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average trading volume of 117,600 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Trading of Agile Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in shares of Agile Therapeutics by 1.1% during the first quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock worth $319,000 after purchasing an additional 16,104 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Agile Therapeutics by 281.3% in the first quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Agile Therapeutics during the second quarter worth about $108,000. Virtu Financial LLC acquired a new stake in shares of Agile Therapeutics during the fourth quarter worth about $32,000. Finally, State Street Corp acquired a new stake in Agile Therapeutics during the 2nd quarter worth $32,000.

Agile Therapeutics Price Performance

Shares of AGRX stock opened at $2.08 on Friday. The company has a 50-day moving average of $2.71 and a two-hundred day moving average of $2.77. The firm has a market cap of $4.01 million, a PE ratio of -0.05 and a beta of 1.13. Agile Therapeutics has a 1-year low of $2.00 and a 1-year high of $22.70.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Agile Therapeutics in a research report on Wednesday, June 7th. StockNews.com started coverage on Agile Therapeutics in a report on Thursday, August 17th. They issued a “hold” rating on the stock.

Get Our Latest Stock Analysis on Agile Therapeutics

About Agile Therapeutics

(Get Free Report)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.